Results 71 to 80 of about 907 (158)

Lipid A Variants Activate Human TLR4 and the Noncanonical Inflammasome Differently and Require the Core Oligosaccharide for Inflammasome Activation. [PDF]

Infect Immun, 2022
Alexander-Floyd J, Bass AR, Harberts EM, Grubaugh D, Buxbaum JD, Brodsky IE, Ernst RK, Shin S.   +7 more
europepmc   +1 more source

A pilot study to develop assessment tools for Group A Streptococcus surveillance studies. [PDF]

PeerJ, 2023
Pickering J, Sampson C, Mullane M, Sheel M, Barth DD, Lane M, Walker R, Atkinson D, Carapetis JR, Bowen AC.   +9 more
europepmc   +1 more source

Tumor-informed liquid biopsy detection of structural variants in high grade serous ovarian cancer. [PDF]

Oncoscience
Li J, Takamatsu S, Brodsky AL, Welte T, Calzoncinth K, Vuttaradhi VK, Celestino J, Lawson B, Hillman RT.   +8 more
europepmc   +1 more source

Platelet dysfunction in chronic kidney disease arises from bone marrow remodeling and megakaryocyte reprogramming. [PDF]

Blood Adv
Carminita E, Camacho V, Branfield S, Walsey E, Barrachina MN, Tabang DN, Lee DH, Becker IC, Brodsky SV, Issa SM, Gendron N, Machado S, Wolberg AS, Steen H, Kerlin B, Machlus KR, Zarjou A, Italiano JE.   +17 more
europepmc   +1 more source

Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials. [PDF]

NPJ Parkinsons Dis
Pagano G, Trundell D, Simuni T, Pavese N, Marek K, Postuma RB, Shariati N, Monnet A, Moore E, Davies EW, Svoboda H, Pross N, Bonni A, Nikolcheva T, PASADENA Investigators, Prasinezumab Study Group.   +15 more
europepmc   +1 more source

Joseph Brodskys litterära exil

, 2010
Nobel Prize Laureate Joseph Brodsky is a key figure in Soviet Russian literature. Expelled from the USSR in 1972, he became a US citizen in 1977 and Poet Laureate of the United States in 1991. In this essay, I have sought to examine the state of exile perceived in Brodsky’s poems.
openaire   +1 more source

Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial. [PDF]

Lancet Haematol, 2022
DeZern AE, Eapen M, Wu J, Talano JA, Solh M, Dávila Saldaña BJ, Karanes C, Horwitz ME, Mallhi K, Arai S, Farhadfar N, Hexner E, Westervelt P, Antin JH, Deeg HJ, Leifer E, Brodsky RA, Logan BR, Horowitz MM, Jones RJ, Pulsipher MA.   +20 more
europepmc   +1 more source

Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials. [PDF]

NPJ Parkinsons Dis
Pagano G, Trundell D, Simuni T, Pavese N, Marek K, Postuma RB, Shariati N, Monnet A, Moore E, Davies EW, Svoboda H, Pross N, Bonni A, Nikolcheva T, PASADENA Investigators, Prasinezumab Study Group.   +15 more
europepmc   +1 more source

The molecular grammar of protein disorder guiding genome-binding locations. [PDF]

Nucleic Acids Res, 2023
Jonas F, Carmi M, Krupkin B, Steinberger J, Brodsky S, Jana T, Barkai N.   +6 more
europepmc   +1 more source

Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab. [PDF]

NPJ Digit Med
Taylor KI, Lipsmeier F, Scelsi MA, Volkova-Volkmar E, Rukina D, Popp W, Lambrecht S, Anzures-Cabrera J, Summers D, Abt M, Monnet A, Kilchenmann T, Schjodt-Eriksen J, Essioux L, Kustermann T, Zago W, Svoboda H, Nikolcheva T, Postuma RB, Pagano G, Lindemann M, PASADENA Investigators, Prasinezumab Study Group.   +22 more
europepmc   +1 more source